Search

N-cyclohexyltaurine

PAC-113

PAC-113 is targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction. … PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.

Dermatophagoides pteronyssinus

This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

Medroxyprogesterone acetate

[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.[L8657]

Pantoprazole

[A177577, A177580] Pantoprazole doses should be slowly lowered, or tapered, before discontinuing as rapid discontinuation of PPIs such as pantoprazole may cause a rebound effect and a short term increase … [FDA Label] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread.

PAC-1

PAC-1 has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others.

Prochlorperazine

Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management … It was shown to also block histaminergic, cholinergic and noradrenergic receptors.[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956.

Ulobetasol

[L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]

PAT-1251

PAT-1251 is under investigation in clinical trial NCT04054245 (PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocytosis Myelofibrosis

Idarubicin

The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.